The present invention is based in part on the identification of Fbxw7 as a biomarker predictive of responsiveness to anti-immune checkpoint therapies.

An in vitro co-culture system comprising cancer-associated fibroblasts (CAFs) and cancer cells for producing and maintaining cancer stem cells and uses thereof for identifying agents capable of reducing cancer cell stemness. Also disclosed herein are a paracrine network through which CAFs facilitate production and/or maintenance of cancer stem cells and the use of components of such a paracrine network for prognosis purposes and for identifying cancer patients who are likely to respond to certain treatment.

A method of determining invasion potential of a tumor cell includes exposing a tumor cell to an activity sensor; after exposing the tumor cell to the activity sensor, stimulating the tumor cell to cause a response in the cell that is reported by the activity sensor; detecting the level of response after stimulation of the tumor cell; and determining the invasion potential of the tumor cell based on the response. A system for determining the invasion potential of a tumor cell includes a sample stage that supports the tumor cell; a stimulator that focuses energy on the tumor cell to stimulate the tumor cell; and an imaging apparatus that observes an effect of the beam on the tumor cell.

Provided herein are compositions and methods for the treatment of cancer by inhibition of -catenin or a -catenin pathway. In particular, inhibitors of -catenin and/or the Wnt/p-catenin signaling pathway are employed prevent or reverse evasion of immune response or immunotherapy by cancers.

Disclosed are methods for treating a cancer in a patient. The method comprises: (a) defining a set of substances targeting pathogenic genes identified by screening of a sample of cancer cells from a patient by NGS or other technique, (b) identifying two or more target genes in the cancer cells, each of which containing an actionable mutation and (c) testing, using in vitro culture cell experiments, the efficacy of one or more substances (administered sequentially or concurrently) targeting the actionable mutation for each of the two or more target genes identified and (d) designating potential efficacious therapeutic options that will be used to treat the patient's cancer.

The present disclosure provides a method for screening, isolating and purifying analytes.

Provided herein are chromatin protection therapeutics (CPTs) and methods of targeting chromatin heterogeneity for the treatment of cancer therewith. In particular compositions and methods are provided that target physical variations in chromatin topology, reduce chromatic heterogeneity, and treat cancer or inhibit the development of resistance to other cancer therapeutics.

A polynucleotide, which is a novel causative gene for cancer, is elucidated, and, based on this finding, provided are a method for detecting the polynucleotide, or a polypeptide encoded by the polynucleotide; a kit and a primer set for the detection; a method for screening an inhibitor of the polypeptide; and a pharmaceutical composition for treating a cancer containing the inhibitor. In the detection method of the present invention, an NTRK3 fusion protein, or a fusion gene encoding the fusion protein, or an ETV6 fusion protein, or a fusion gene encoding the fusion protein, in a sample derived from the digestive system obtained from a subject, is detected.

An in vitro co-culture system comprising cancer-associated fibroblasts (CAFs) and cancer cells for producing and maintaining cancer stem cells and uses thereof for identifying agents capable of reducing cancer cell stemness. Also disclosed herein are a paracrine network through which CAFs facilitate production and/or maintenance of cancer stem cells and the use of components of such a paracrine network for prognosis purposes and for identifying cancer patients who are likely to respond to certain treatment.

The invention relates, in part, to methods to identify compounds to treat a phytoparasitic nematode infection and/or reduce phytoparasitic nematode contamination, and to methods and compositions to treat phytoparasitic nematode infections and to reduce phytoparasitic nematode contamination of a substrate such as, but not limited to: a plant, agricultural medium, or soil.